partnershipMemo Therapeutics and Ono Pharmaceutical enter partnership Antibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field. more ➔
Healthcare investments in Catalonia at record highCatalonia’s healthcare start-ups raised €238m in 2021, a new record and 4% up from 2020. Four fifth (83%) of VC came from international investors. more ➔
cardiologyEU Health Union ignoring cardiologyThe European Council has adopted three regulations aimed at improving pandemic preparedness, which together with two other pillars complete the EU Health Union. more ➔
partnershipAudi and Krajete create CO2 air capture plantAutomotive company Audi AG and gas fermentation specialist Krajete GmbH are building a highly effective industrial-scale CO2 Direct Air Capturing plant in Linz. more ➔
Novel FoodSolar Food’s protein from carbon dioxide gets authorisationFinnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein. more ➔
M&ABone Therapeutics merges with Medsenic and changes nameBone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a €40m deal and changed its name into BioSenic. more ➔
financingResolve Biosciences secures US$71m in fundingMolecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors. more ➔
financingEnhanc3D Genomics raises £10m in Series A financingCambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors. more ➔
financingUnivercells SA raises €44m in first close of its Series DBelgian CDMO Univercells SA has raised €44m through the first close of its Series D financing round led by Belgian and international investors. I more ➔
SepsisAdrenomed set to start pivotal trial in sepsisGerman Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study. more ➔
